| Old Articles: <Older 6231-6240 Newer> |
|---|
 |
The Motley Fool
March 8, 2010
Brian Orelli |
Pfizer Still Dealing With Antitrust Issues The pharma giant sells off some more animal health assets.   |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
March 5, 2010
Brian Orelli |
How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot. |
BusinessWeek
March 4, 2010
Amanda Bennett |
Lessons of a $618,616 Death Two years after her husband's death, the author's cover story examines the costs of keeping one man alive to fight in the face of a dismal prognosis. |
The Motley Fool
March 4, 2010
Brian Orelli |
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
March 3, 2010
Brian Orelli |
Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration. |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
Inc.
March 1, 2010
Kasey Wehrum |
The Business of Mission County Hospital A look at the companies that supply the California hospital with virtual records, equipment repair, and laundry services |
| <Older 6231-6240 Newer> Return to current articles. |
